<DOC>
	<DOCNO>NCT02610140</DOCNO>
	<brief_summary>The main purpose 15743 study ass efficacy safety anetumab ravtansine versus vinorelbine progression free survival patient stage IV mesothelin overexpressing malignant pleural mesothelioma ( MPM ) . 210 eligible patient randomize receive either anetumab ravtansine every three week weekly vinorelbine . Treatment continue centrally confirm disease progression ( PD ) another criterion meet withdrawal study . Patients enter follow phase capture safety endpoint data require . Efficacy measure evaluate progression free survival randomization . Radiological tumor assessment perform defined time point patient 's disease progress . Blood sample collect safety , pharmacokinetic biomarker analysis . Archival fresh biopsy tissue may also collect central pathology review biomarkers .</brief_summary>
	<brief_title>Phase II Anetumab Ravtansine 2nd Line Treatment Malignant Pleural Mesothelioma ( MPM )</brief_title>
	<detailed_description />
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Histological documentation malignant pleural mesothelioma ( MPM ) overexpressing mesothelin Unresectable locally advance metastatic MPM locally confirm progression 1st line treatment platinum combination pemetrexed . Patients must measurable disease Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 0 1 Life expectancy least 3 month . Adequate bone marrow , liver renal function Left ventricular ejection fraction ( LVEF ) â‰¥ 50 % low limit normal ( LLN ) accord local institution range normality . More 1 previous systemic anticancer therapy line Patients corneal epitheliopathy eye disorder may predispose patient condition discretion ophthalmologist . Brain metastasis , meningeal tumour metastases central nervous system Evidence history bleed diathesis . Ongoing active infection ( bacterial , fungal , viral ) National Cancer Institute 's Common Terminology Criteria Adverse Events ( NCICTCAE ) version 4.03 Grade &gt; 2 . Preexisting cardiac condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>